Novartis CEO calls for simpler biosim rules, end to rebate wall by Eric Sagonowsky Friday, April 13, 2018 Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.
FiercePharmaAsia—Novartis, Samsung Bioepis, Takeda and more by Angus Liu Friday, April 13, 2018 Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.
No March madness for pharma ad spending as Humira tops list by Beth Snyder Bulik Wednesday, April 11, 2018 AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.
AbbVie's Humira wins another biosim reprieve with Biogen deal by Eric Sagonowsky Thursday, April 5, 2018 AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.
Celgene, AbbVie extract pricing gains as Gilead, J&J meds net less by Eric Sagonowsky Tuesday, April 3, 2018 Higher net prices for Humira and Revlimid fueled growth in the fourth quarter for AbbVie and Celgene, respectively, a report found.
Pfizer's Ibrance joins February's TV ad-spending leaders by Beth Snyder Bulik Friday, March 23, 2018 Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.
AbbVie, AZ investors reaped pharma's biggest gains in 2017 by Eric Sagonowsky Thursday, March 15, 2018 Despite uncertainty heading into 2017, most drug stocks escaped the stagnation of 2016—some far more than others.
Here's a DTC shocker: Pharma ad spend actually fell in 2017 by Beth Snyder Bulik Tuesday, March 13, 2018 As four of pharma's top five advertisers cut spending, DTC outlays dropped in 2017 for the first time since the 2008 recession, Kantar says.
AbbVie, Pfizer lead pharma TV ad in 2018 start by Beth Snyder Bulik Wednesday, February 7, 2018 It’s a new year of TV ad spending in pharma, and AbbVie's Humira and Pfizer's Lyrica started with a bang at more than $35 million each last month.
AbbVie hikes 2018 forecast thanks to U.S. tax changes by Arlene Weintraub Friday, January 26, 2018 The benefits of the upcoming tax overhaul will be so great that AbbVie is planning $2.5 billion in capital projects in the U.S.
